---
figid: PMC8206805__fimmu-12-689132-g001
figtitle: Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in
  the Treatment of Advanced Non-Small Cell Lung Cancer
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8206805
filename: fimmu-12-689132-g001.jpg
figlink: /pmc/articles/PMC8206805/figure/f1/
number: F1
caption: Monoclonal antibodies and small molecules targeting VEGF/VEGFR signaling
  in tumor angiogenesis. Monoclonal antibodies and small molecule TKIs targeting the
  VEGFA/VEGFR-2/PLCγ/Raf/PI3K signaling pathway could inhibit tumor angiogenesis and
  improve the efficiency of anticancer treatments. VEGF, Vascular Endothelial Growth
  Factor; VEGFR, Vascular Endothelial Growth Factor Receptor; TKI, Tyrosine Kinase
  Inhibitor; PI3K, Phosphoitide 3-Kinase; AKT, serine/threonine-specific protein kinase;
  mTOR, mammalian target of rapamycin; PLCγ, Phospholipase C γ; PI3P, Phosphatidylinositol
  3-Phosphate; IP3, Inositol Triphosphate; DAG, Diacyl Glycerol; pKC, Protein Kinase
  C; MEK, Mitogen-activated protein kinase; MAPK, Mitogen Activated Protein Kinase.
papertitle: The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors
  in the Treatment of Advanced Non-Small Cell Lung Cancer.
reftext: Sijia Ren, et al. Front Immunol. 2021;12:689132.
year: '2021'
doi: 10.3389/fimmu.2021.689132
journal_title: Frontiers in Immunology
journal_nlm_ta: Front Immunol
publisher_name: Frontiers Media S.A.
keywords: NSCLC | immunotherapy | immune checkpoint blockade | angiogenesis inhibitors
  | combination therapy | tumor microenvironment
automl_pathway: 0.9167969
figid_alias: PMC8206805__F1
figtype: Figure
redirect_from: /figures/PMC8206805__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8206805__fimmu-12-689132-g001.html
  '@type': Dataset
  description: Monoclonal antibodies and small molecules targeting VEGF/VEGFR signaling
    in tumor angiogenesis. Monoclonal antibodies and small molecule TKIs targeting
    the VEGFA/VEGFR-2/PLCγ/Raf/PI3K signaling pathway could inhibit tumor angiogenesis
    and improve the efficiency of anticancer treatments. VEGF, Vascular Endothelial
    Growth Factor; VEGFR, Vascular Endothelial Growth Factor Receptor; TKI, Tyrosine
    Kinase Inhibitor; PI3K, Phosphoitide 3-Kinase; AKT, serine/threonine-specific
    protein kinase; mTOR, mammalian target of rapamycin; PLCγ, Phospholipase C γ;
    PI3P, Phosphatidylinositol 3-Phosphate; IP3, Inositol Triphosphate; DAG, Diacyl
    Glycerol; pKC, Protein Kinase C; MEK, Mitogen-activated protein kinase; MAPK,
    Mitogen Activated Protein Kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - PIG-F
  - Akt
  - Mtor
  - Tor
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - sl
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - Mtk
  - MKP-4
  - p38b
  - rl
  - Erk7
  - FLT1
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - PIGF
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PLCG1
  - PLCG2
  - KDR
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - EPHB2
---
